Answers are grounded in this paper and cite their sources.
Case report shows genomic instability and clonal evolution in secondary plasma cell leukemia, highlighting tumor heterogeneity in multiple myeloma.
Secondary plasma cell leukemia (sPCL) is a rare, aggressive manifestation of multiple myeloma (MM). We report a 75‐year‐old Japanese man with anemia as the chief complaint and IgG‐λ MM that rapidly progressed to sPCL. Whole genome sequencing using Canopy revealed a major clone with a monoallelic TP53 mutation. During progression, a subclone with a biallelic TP53 mutation expanded, and the 1q21 copy number increased. Single‐cell RNA‐sequencing identified an emergent PCL population with high CKS1B expression. These data demonstrate genomic instability and clonal evolution during sPCL development, underscoring the need for approaches accounting for tumor heterogeneity in MM. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: